Skip to main content

Table 1 Description of the patients recruited for the study

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Samples

Stage

Grade

Treatment cycles

Age

Overall survival

Ascites 1

IIIc

High Grade Serous

Carboplatin and Paclitaxel 6 cycle

39 years at diagnosis

3 years and 7 months

Doxorubicin Pegylated Liposomal 9 cycles

Gemcitabine and Carboplatin 3 cycles

Paclitaxel (12 treatments in cycle 1, 3 treatments in cycles 3 through to 9)

Ascites 2

IIa

High Grade Serous

Carboplatin 5 cycles

78 years at diagnosis

6 months

Ascites 3

Unknown

Not Graded

Carboplatin and Paclitaxel 4 cycles

59 years at diagnosis

5 months as of 20/11/2012

Ascites 4

Unknown

Adenocarcinoma NOS

Carboplatin and Paclitaxel 6 cycles

75 years at diagnosis

1 year 8 months

Tamoxifen 2 cycles

Doxorubicin Pegylated Liposomal 4 cycles

Ascites 5

IIc

High Grade Serous

Carboplatin and Paclitaxel 4 cycles, Topotecan 1 cycle

64 years at diagnosis

5 months

Ascites 6

IIIc

High Grade Serous

Carboplatin and Paclitaxel 6 cycles

52 years at diagnosis

2 years 5 months

AMG-386 182 Trial 8 cycles

Paclitaxel 3 cycles

Paragon Trial 2 cycles

Carboplatin single agent 3 cycles

Cyclophosphamide 2 cycles

Ascites 7

IIIc

High Grade Serous

Carboplatin and Paclitaxel 9 cycles

59 years at diagnosis

2 years 6 months

Cisplatin 4 cycles

Cyclophosphamide 2 cycles

Ascites 8

IV

Adenocarcinoma NOS

Carboplatin and Paclitaxel 6 cycles

67 years at diagnosis

2 years 6 months

Gemcitabine and Carboplatin 6 cycles

Ascites 9

Unknown

Adenocarcinoma NOS

Cyclophosphamide 3 cycles

 

2 years 8 months

Carboplatin and Paclitaxel 6 cycles

65 years at diagnosis

MORAb Trial 9 cycles

Doxorubicin Pegylated Liposomal 3 cycles

Ascites 10

IIIc

High Grade Serous

Doxorubicin Pegylated Liposomal 3 cycles

55 years

5 years 5 months

ICON 7 Trial 18 cycles

ICON 6 Trial 6 cycles

Paragon Trial 1 cycle

Paclitaxel 6 cycles

  

Ascites 11

IIIc

High Grade Serous

Hormonal Therapy Tamoxifen

69 years at diagnosis

7 years 11 months

Topotecan Hydrochloride 2 cycles

Carboplatin and Paclitaxel 6 cycles

Carboplatin single agent 6 cycles

Gemcitabine and Carboplatin 6 cycles

Carboplatin single agent 6 cycles

Cyclophosphamide 6 cycles

Doxorubicin Pegylated Liposomal 4 cycles

Paclitaxel 3 cycles

Ascites 12

IIIc

High Grade Serous

Doxorubicin Pegylated Liposomal 3 cycles Carboplatin and Paclitaxel 6 cycles

59 years at diagnosis

2 years 11 months as of 21/05/2013

Gemcitabine and Carboplatin 6 cycles

Ascites 13

IIIc

High Grade Serous

Doxorubicin Pegylated Liposomal 4 cycles

53 years at diagnosis

2 years 11 months as of 21/05/2013

Carboplatin and Paclitaxel 6 cycles

AMG-386 182 9 cycles

Paclitaxel 6 cycles

Cyclophosphamide 2 cycles

Topotecan 2 cycles

Ascites 14

IV

High Grade Serous

Carboplatin 1 cycle

46 years at diagnosis

2 years 6 months as of 13/08/2013

Carboplatin and Paclitaxel 6 cycles

Ascites 15

IIIc

Not Graded

Carboplatin 5 cycles

76 years at diagnosis

1 year and 8 months

Cyclophosphamide 7 cycles

Paragon Trial 3 cycles

  1. NOS, Not Otherwise Specified.